Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer

The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR Agents

“…A previous study (BOND I) evaluating treatment of metastatic colorectal cancer with cetuximab/irinotecan reported a 23% response rate and time to progression of 4 months (88). In BOND II, Saltz et al (174) showed that the addition of bevacizumab to the treatment regimen produced a 37% response rate with median time to progression of 7.9 months. The response rate when patients were treated with cetuximab alone was 11% and time to progression was 1.5 months (88).…”

“…In metastatic colorectal cancer for which both bevacizumab and cetuximab are approved for use, a randomized phase II trial (BOND II) examined the efficacy and safety of concurrent administration of bevacizumab plus cetuximab, with and without irinotecan, in irinotecan-refractory disease (174). Adding bevacizumab to cetuximab or cetuximab/irinotecan improved outcomes compared with historical data for these agents.…”

Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer

“…The Bowel Oncology with Cetuximab Antibody (BOND)-2 trial investigated the feasibility and efficacy of bevacizumab added to cetuximab alone or to cetuximab plus irinotecan in patients with irinotecanrefractory disease (Saltz et al, 2005). In spite of the limitations of this small trial, preliminary data were encouraging, with 23 and 38% RRs, and 6.9-and 8.5-month TTPs, respectively, which appear significantly better than those of historical controls from the BOND-1 trial (RR, 11 and 23%; TTP, 1.5 and 4 months).…”

Advances in the Treatment of Metastatic Colorectal Cancer

“…Such a study was conducted in irinotecan-refractory patients [37]. In this comparison of cetuximab, bevacizumab, and irinotecan (CBI) versus cetuximab and bevacizumab (CB) alone, the response rate and median TTP in the CBI arm were impressive for this population of patients with chemotherapy-refractory tumors (37% and 7.9 months, respectively).…”

“…Because of the large number of patients now receiving bevacizumab, subsequent investigations will evaluate this combination in patients who have manifested progression of disease while receiving both chemotherapy and bevacizumab. It is also uncertain whether these patients have disease that is resistant to or remains sensitive to continued exposure to bevacizumab [37].…”